Zhongguancun, the frontier track of the card position, is poised for the ＂Valley of Life＂
The cross-integration of science and technology is promoting the continuous progress in the field of life sciences, and life sciences are increasingly becoming the core of a new round of scientific and technological revolution and industrial transformation. Recently, a reporter from beijing business today walked into Zhongguancun Life Science Park with the Beijing Municipal Development and Reform Commission to explore new changes in the medical and health industry in Beijing, Tianjin and Hebei. According to Beijing's deployment, Zhongguancun Life Science Park will be built into a world-leading "Valley of Life". As one of the parks with the most concentrated innovation resources in China's life sciences, Zhongguancun Independent Innovation Demonstration Zone, National Service Industry Expansion and Opening-up Comprehensive Demonstration Zone and Free Trade Pilot Zone are superimposed, which brings great opportunities for promoting the development of medical and health industry in Beijing, Tianjin and Hebei.
Building the first international research hospital in China
In Zhongguancun Life Science Park in Changping District, the first international research hospital in China has entered the debugging stage before operation.
As the first international research hospital in China with the strategic goal of difficult and serious diagnosis and treatment, clinical research and the transformation of biomedical and equipment industries, Beijing Gaobo Hospital, located in Zhongguancun Life Science Park, has now entered the final sprint stage before putting into use. On the spot, it can be seen that the staff are nervously carrying out large-scale medical equipment commissioning and other work.
According to Gao Nan, vice president of Gaobo Medical Group, Beijing Gaobo Hospital is characterized by "small outpatient service and large scientific research", and has carried out medical cooperation with more than 60 hospitals in Beijing, Tianjin and Hebei. After it is put into operation, it is expected to complete 400-600 clinical trials and clinical studies every year.
At the same time, it also cooperates with the world's top medical institutions and universities in global multi-center clinical research, builds a clinical application and transformation center for drug research and development, a platform for clinical discovery transformation, an innovative research center for clinical experts and scientists, and a diagnosis and treatment center for difficult and severe diseases, and introduces a clinical medical research system, a service system and a personnel training system that are in line with the world's top level, effectively solving the bottleneck problem of long clinical research cycle and high cost of enterprises, accelerating the transformation process of medical research and development achievements, and further improving the innovation chain of Beijing medical and health industry.
It is understood that in order to lay out the clinical research business in advance, Gaobo Medical Group has registered three companies engaged in clinical transformation and application, hospital management services and brain science business in the Life Science Park, and has been closely linked with upstream and downstream enterprises such as biopharmaceuticals, medical devices and medical laboratories in the park to continuously promote the research and application of new therapies, new drugs and new devices.
It is reported that the Beijing Gaobo Hospital project is an important strategic deployment of Beijing-Tianjin-Hebei and an important measure to promote the high-quality development of the medical and health industry in Changping District, and was listed in the "Three 100" key projects in Beijing in 2020.
Aggregation of ecological factors in the whole chain industry
In another part of Zhongguancun Life Science Park, Beijing Wan Tai Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as "Wan Tai Bio") is also making breakthroughs in diagnostic reagents.
As a major production base of AIDS diagnostic reagents in Asia-Pacific and a well-known production base of immunodiagnostic reagents in China, Wan Tai Bio occupies an important position in the domestic market with its core products such as in vitro diagnostic reagents and cervical cancer vaccine. During the epidemic period, the nasal spray vaccine (dNS1-RBD) jointly developed by Wan Tai Bio, Xiamen University and Hong Kong University is the first nasal spray preventive vaccine for COVID-19 to enter human clinical trials in the world.
At present, the first and second phases of Zhongguancun Life Science Park have gathered more than 500 innovative medical and health enterprises, including Boao Bio, Novo Nordisk, Wan Tai Bio, Baekje Shenzhou, Nuocheng Jianhua, Fanzi, etc. At the same time, they have settled in Beijing protein Group Research Center, Beijing Life Science Research Institute, Beijing Institute for Drug Control, Zhongguancun Life Science Joint Innovation Service Center, Beijing Brain Science and Brain-like Research Center, Zhongguancun Life Science Park Medical Science and Technology Center, etc.
Seize the opportunity of "two districts" construction, promote the opening of the whole biomedical industry chain, and the Beijing Pharmaceutical Medical Device Innovation Service Station was officially listed and put into operation in Zhongguancun Life Science Park; The city's first free trade group medical and health industry promotion policy was introduced, benefiting 71 enterprises. The system layout is a key common platform. The park has 33 platforms such as CXO, experimental animals and AI drug research and development, including the only public service of clinical sample resources for major diseases in the city and the first CDMO platform in CGT field in Beijing.
In the next step, Zhongguancun Life Science Park will focus on cell and gene therapy (CGT), a new generation of antibody drugs, new vaccines, synthetic biology and other sub-sectors in combination with the new round of scientific and technological revolution and industrial transformation trends, closely focusing on the two core driving forces of "biological+"and "digital+",so as to create a new highland for cell and gene therapy (CGT); Pay close attention to AI new drug research and development, AI aided diagnosis, AI medical service, brain-like intelligence and brain-computer interface, accelerate the introduction of high-quality incremental resources for the international community, and build a global "star of tomorrow". Give full play to the R&D and innovation advantages of Zhongguancun Life Science Park, accurately block the frontier track, and accelerate the breakthrough of cutting-edge technology and the incubation of high-tech enterprises.
Beijing business today reporter Zhang Qiqi
Declaration: All article resources on this website, unless otherwise specified or labeled, are collected from online resources. If the content on this website infringes on the legitimate rights and interests of the original author, you can contact this website to delete it.
